£34,619 - £43,592 per annum: Barts Cancer Institute , Queen Mary University London: Department: Barts Cancer Institute Salary: £34,619 - £43,592 per annum (Grade 4) Reference: QMUL31619 Location: Charterhouse Square Date posted: 19 Ma London, Greater London, England

Notice NOT-OD-23-129 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-206 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).

Funding Opportunity PAR-23-198 from the NIH Guide for Grants and Contracts. The NIAID New Innovator Award supports a postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.

Notice NOT-OD-23-134 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-136 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-135 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-240 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-24-120 from the NIH Guide for Grants and Contracts. The goal of this phased FOA (either R33/R61 or UG3/UH3) is to accelerate the development of sensitive biomarkers/tools to predict individual treatment-response between two or more existing treatments for depression. In phase 1 (up to 2 years) preliminary studies (e.g., retrospective secondary analyses of data from completed clinical trials and/or in nimble, fast-fail pilot studies) will de-risk the test technology demonstrating that there is enough signal for clinical utility (futility analyses, ROC curves, and/or effect size will be evaluated as go/no-go criteria). Phase 2 (up to 5 years) innovators will prospectively test the efficacy of the biomarker/tool in large-scale biomarker/tool-stratified clinical trials with the goal of beating standard-of-care decision-making (i.e., clinician/patient treatment assignment will be the CTRL group vs the test).

Funding Opportunity PAR-23-166 from the NIH Guide for Grants and Contracts. The purpose of theNative American Research Centers for Health (NARCH) program is to fund federally-recognized American Indian/Alaska Native (AI/AN) tribes and tribal organizations to support health-related research, research career enhancement, and research infrastructure enhancement activities.

£50000 - £60000 per annum: CK Group: CK Group are recruiting for a Senior Protein Scientist to join a biotechnology company based in London on a permanent basis. The Company: Our client... London

Notice NOT-EB-23-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-265 from the NIH Guide for Grants and Contracts

Between £29,842 and £41,438 per annum: Rothamsted Research: An exciting opportunity has arisen for a Bioinformatics Scientist  to join a multidisciplinary programme of researchers using multi-omic data to di... Harpenden, Hertfordshire

Notice NOT-DA-23-022 from the NIH Guide for Grants and Contracts

Research Technologist II Requisition ID #: 32584 Job Category: Research Employment Type: Full Time Experience Level: Entry Level City, State: Milwaukee, WI…
From Medical College of Wisconsin - Thu, 01 Jun 2023 03:08:33 GMT - View all Milwaukee, WI jobs

From £41,935 with benefits, subject to skills and experience.: The Francis Crick Institute: Postdoctoral Positions Join us at the Francis Crick Institute We are looking for scientists to join our community of more than 400 postdocs tacklin... London (Central), London (Greater) (GB)

From £43,600 with benefits, subject to skills and experience: The Francis Crick Institute:  Data Engineer / Bioinformatician- AZ-Crick-Imperial College: Molecular Glue Discovery Partnership Reporting to: Karen Ambrose, Chief Data Officer,... London (Central), London (Greater) (GB)

Funding Opportunity RFA-DK-23-013 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDDK R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. This FOA solicits applications to establish summer research institutes for qualified undergraduates to participate in summer research experiences relevant to the mission of the Division of Kidney, Urologic and Hematologic Diseases/NIDDK (NIDDK/DKUH).

Funding Opportunity RFA-CA-23-024 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO), issued by the National Cancer Institute (NCI), is to invite competing continuation applications for cooperative agreement awards from current recipients of the NCI-supported Cooperative Human Tissue Network (CHTN). CHTN with all individual CHTN recipients (referred to as CHTN Divisions) collectively form the CHTN national resource. Presently, the organizational structure of the Network comprises six Divisions. The goal of the CHTN is to collect and distribute to investigators high-quality human tissue specimens to facilitate basic and translational cancer research. Such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, and prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on the prospective collection and distribution of samples upon specific investigators requests. Samples to be collected from patients include pre-cancerous, malignant, and benign neoplastic tissues, as well as tissues with non-neoplastic diseases and normal tissues. Since its establishment by the NCI in 1987, the CHTN has provided more than 1,350,000 malignant, benign, diseased, and uninvolved (normal adjacent) high-quality human tissue specimens from a wide variety of organ sites to over four thousand investigators.